Aerovate Therapeutics Inc (AVTE) Financials
$2.68
As on 28-Apr-2025 16:28EDT
Market cap
$78 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
35.6
Div. Yield
0 %
Income Statement ($ Mln) |
TTM | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Operating Revenue
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cost of Revenue
|
0.03
|
--
|
0.10
|
0.07
|
0.02
|
0.00
|
|||||
|
Gross Profit
|
-0.03
|
--
|
-0.10
|
-0.07
|
-0.02
|
0.00
|
|||||
|
Operating Expenses
|
53.37
|
74.60
|
81.41
|
53.24
|
23.02
|
8.89
|
|||||
|
Operating Profit (EBIT)
|
-53.37
|
-74.60
|
-81.41
|
-53.24
|
-23.02
|
-8.89
|
|||||
|
Other Income
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Profit before Tax
|
-48.91
|
-69.57
|
-75.47
|
-51.49
|
-22.96
|
-9.61
|
|||||
|
Provision for Tax
|
-2.46
|
0.06
|
0.06
|
0.03
|
0.00
|
-0.57
|
|||||
|
Profit after Tax (Net Income)
|
-48.96
|
-69.63
|
-75.52
|
-51.51
|
-22.96
|
-9.04
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Consolidated Profit
|
--
|
--
|
--
|
--
|
-22.99
|
-9.76
|
Liabilities ($ Mln) |
TTM | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Shareholder's Funds
|
75.05
|
76.43
|
109.46
|
126.74
|
172.42
|
-13.34
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Non-Current Liabilities
|
0.07
|
0.07
|
0.33
|
0.78
|
0.40
|
16.29
|
|||||
|
Current Liabilities
|
2.42
|
3.83
|
17.64
|
7.78
|
2.55
|
1.77
|
|||||
|
Total Liabilities
|
79.95
|
80.33
|
127.42
|
135.30
|
175.36
|
4.72
|
Assets ($ Mln) |
TTM | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Non-Current Assets
|
0.16
|
0.22
|
3.19
|
3.81
|
1.03
|
0.04
|
|||||
|
Current Assets
|
77.37
|
80.12
|
124.23
|
131.50
|
174.33
|
4.68
|
|||||
|
Total Assets
|
154.91
|
80.33
|
127.42
|
135.30
|
175.36
|
4.72
|
|||||
|
Total Debt*
|
0.31
|
0.42
|
0.68
|
1.09
|
0.57
|
--
|
|||||
|
Net Current Assets
|
--
|
76.29
|
106.60
|
123.71
|
171.78
|
2.90
|
Cashflow ($ Mln) |
TTM | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cash From Operating Activities
|
--
|
-71.20
|
-56.78
|
-39.12
|
-27.40
|
-7.86
|
|||||
|
Cash Flow from Investing Activities
|
--
|
--
|
--
|
--
|
-113.43
|
-113.43
|
|||||
|
Cash from Financing Activities
|
--
|
25.43
|
46.00
|
0.40
|
190.46
|
8.92
|
|||||
|
Net Cash Inflow / Outflow
|
--
|
--
|
--
|
--
|
--
|
--
|
Financials Ratios |
TTM | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Adjusted EPS ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash EPS ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Adjusted Book Value ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Dividend per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Flow per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Free Cash Flow per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
Profitability Ratios |
TTM | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
ROCE (%)
|
--
|
-74.48
|
-63.47
|
-34.25
|
-28.77
|
124.79
|
|||||
|
ROE (%)
|
-62.96
|
-74.91
|
-63.95
|
-34.44
|
-28.87
|
106.42
|
|||||
|
ROA (%)
|
-35.32
|
-67.03
|
-57.49
|
-33.16
|
-25.50
|
-219.69
|
|||||
|
EBIT Margin (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Net Margin (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Profit Margin (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
Growth Ratios |
TTM | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue Growth (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EBIT Growth (%)
|
43.46
|
8.37
|
-52.92
|
-131.24
|
-158.99
|
-167.02
|
|||||
|
Net Profit Growth (%)
|
40.43
|
7.80
|
-46.61
|
-124.32
|
-154.04
|
-171.44
|
|||||
|
EPS Growth (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Book Value Growth (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
Valuation Ratios |
TTM | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Price / Earnings
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Price / Book Value
|
35.57
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Dividend Yield (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EV/EBITDA
|
-9.33
|
1.05
|
1.50
|
2.41
|
7.25
|
--
|
|||||
|
Close Price ($)
|
87.85
|
92.75
|
792.05
|
1,025.50
|
412.65
|
--
|
|||||
|
High Price ($)
|
1,134.53
|
1,134.53
|
1,058.40
|
1,077.65
|
1,030.05
|
--
|
|||||
|
Low Price ($)
|
43.75
|
43.75
|
329.35
|
270.90
|
309.05
|
--
|
|||||
|
Market Cap ($ Cr)
|
77.68
|
--
|
--
|
--
|
--
|
--
|
Solvency Ratios |
TTM | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debt to Equity
|
--
|
0.01
|
0.01
|
0.01
|
0.00
|
--
|
|||||
|
Short term debt to equity ratio
|
0.00
|
0.01
|
0.00
|
0.01
|
0.00
|
--
|
|||||
|
Current Ratio
|
32.01
|
20.93
|
7.04
|
16.90
|
68.37
|
2.64
|
|||||
|
Quick Ratio
|
32.01
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Interest Coverage
|
--
|
--
|
--
|
-30.40
|
-354.18
|
-118.52
|
Operating Efficiency Ratios |
TTM | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debtors to sales (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Asset Turnover
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Receivable days
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Inventory Days
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Payable days
|
--
|
--
|
9,456.55
|
10,159.86
|
22,158.50
|
210,749.25
|
|||||
|
Cash Conversion Cycle
|
--
|
--
|
--
|
--
|
--
|
--
|